Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
US Patent Number
10,344,095
Publication Date
7-9-2019
Abstract
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
Assignees
University of Kentucky Research Foundation, Lexington, KY (US)
Application Number
11/357,288
Filing Date
02/16/2006
Recommended Citation
Ambati, Jayakrishna, "CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration" (2019). Ophthalmology and Visual Science Faculty Patents. 24.
https://uknowledge.uky.edu/ophthalmology_patents/24
